Drug Profile
Dendrimer enhanced irinotecan - Starpharma
Alternative Names: DEP® irinotecan; DEP® SN38; SN38-SPL9111Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Starpharma
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 23 Oct 2023 Data from the preclinical studies in Gastrointestinal cancer presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference (AACR-NCI-EORTC-2023)
- 11 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 27 Sep 2023 Starpharma files for patent protection for DEP® irinotecan